Ascendis Pharma has emerged as a potential threat to BioMarin’s Voxzogo, reporting phase 3 growth disorder data that exceeded ...

Ascendis Pharma A/S (ASND) said that it has priced its underwritten public offering of 2 million American Depositary Shares or 'ADSs' ...

A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares ...

Ascendis Pharma A/S (ASND) said that it has commenced an underwritten public offering of $300 million of American Depositary Shares ...

In a notable update, Cantor Fitzgerald has reiterated its “Overweight” rating on Ascendis Pharma’s stock. The analyst’s price target remains set at $170, reflecting optimism about the company’s future ...

Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest ...

AstraZeneca's Imfinzi was used before and after surgery in a clinical trial of patients with muscle-invasive bladder cancer — ...

American depositary receipts of Ascendis Pharma A/S rose 15% on topline data from a trial of TransCon CNP, a potential treatment for children with achondroplasia. ADRs were trading around $137. ADRs ...

COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares ...

(RTTNews) - Ascendis Pharma A/S (ASND) said that it has priced its underwritten public offering of 2 million American Depositary Shares or "ADSs" at $150.00 per ADS. Each ADS represents one ...